- |<
- <
- 1
- >
- >|
-
[in Japanese], [in Japanese], [in Japanese], [in Japanese], [in Japane ...2023 Volume 133 Issue 10 Pages 2313-2323
Published: September 20, 2023
Released on J-STAGE: September 20, 2023
JOURNAL FREE ACCESSDownload PDF (485K)
-
[in Japanese]2023 Volume 133 Issue 10 Pages 2325-2336
Published: September 20, 2023
Released on J-STAGE: September 20, 2023
JOURNAL RESTRICTED ACCESS -
[in Japanese]2023 Volume 133 Issue 10 Pages 2337-2345
Published: September 20, 2023
Released on J-STAGE: September 20, 2023
JOURNAL RESTRICTED ACCESS -
[in Japanese]2023 Volume 133 Issue 10 Pages 2347-2353
Published: September 20, 2023
Released on J-STAGE: September 20, 2023
JOURNAL RESTRICTED ACCESS -
[in Japanese]2023 Volume 133 Issue 10 Pages 2355-2361
Published: September 20, 2023
Released on J-STAGE: September 20, 2023
JOURNAL RESTRICTED ACCESSDownload PDF (607K)
-
Shizuka Ozasa, Manami Okuzawa, Satoshi Okuno, Takashi Hashimoto, Hitos ...2023 Volume 133 Issue 10 Pages 2363-2372
Published: September 20, 2023
Released on J-STAGE: September 20, 2023
JOURNAL RESTRICTED ACCESSMembrane therapeutic plasma exchange (mTPE) is widely used in Japan, and central venous catheters are usually used for vascular access. However, central venous access devices can increase the patient burden and sometimes cause catheter infection. We report two cases of pemphigus vulgaris treated with centrifuge therapeutic plasma exchange (cTPE) through peripheral venous access; both were successfully treated without catheter infection. We also compared the efficacies of cTPE with eight patients treated with mTPE in our department in the last five years. cTPE resulted in non-inferior IgG reduction ratios and comparable therapeutic efficacy compared to those of mTPE. cTPE, which can be performed through peripheral venous access, is a good therapeutic option for plasma exchange.
View full abstractDownload PDF (1114K) -
Kinuko Irie, Nobuyuki Kikuchi, Masato Ishikawa, Takashi Ito, Mai Endo, ...2023 Volume 133 Issue 10 Pages 2373-2384
Published: September 20, 2023
Released on J-STAGE: September 20, 2023
JOURNAL RESTRICTED ACCESSWe herein report six cases of bullous pemphigoid that developed after treatment with immune checkpoint inhibitors. Five patients had anti-BP180NC16a antibodies, and one had anti-LAD antibodies. The primary diseases in one case each were malignant melanoma and gastric cancer and renal cell carcinoma and lung cancer in two cases each. The median time from the start of immune checkpoint inhibitor treatment to bullous pemphigoid onset was 72 weeks (38-158 weeks). All but one patient had good responses to immune checkpoint inhibitors for the primary disease; five patients maintainied long-term progression-free survival.
View full abstractDownload PDF (2291K)
-
2023 Volume 133 Issue 10 Pages 2385-2387
Published: September 20, 2023
Released on J-STAGE: September 20, 2023
JOURNAL RESTRICTED ACCESSDownload PDF (361K)
- |<
- <
- 1
- >
- >|